Clovis Oncology Inc. [NASDAQ: CLVS] slipped around -0.11 points on Wednesday, while shares priced at $0.89 at the close of the session, down -11.00%. The company report on October 27, 2022 that Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation titled, “TRITON3: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC Associated with Homologous Recombination Deficiency (HRD)” is being presented by Alan H. Bryce, MD, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic and co-principal investigator of the TRITON3 trial during the session titled, “Novel Clinical Trial Updates” at the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat.
Clovis Oncology Inc. stock is now -67.16% down from its year-to-date (YTD) trading value. CLVS Stock saw the intraday high of $1.03 and lowest of $0.8813 per share. The company’s 52-week high price is 4.76, which means current price is +53.18% above from all time high which was touched on 07/08/22.
Compared to the average trading volume of 3.05M shares, CLVS reached a trading volume of 3997638 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Clovis Oncology Inc. [CLVS]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLVS shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLVS stock is a recommendation set at 3.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Clovis Oncology Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 06, 2022. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $29 to $33. The new note on the price target was released on May 18, 2020, representing the official price target for Clovis Oncology Inc. stock. Previously, the target price had yet another raise to $5, while SVB Leerink analysts kept a Underperform rating on CLVS stock.
The Average True Range (ATR) for Clovis Oncology Inc. is set at 0.09, with the Price to Sales ratio for CLVS stock in the period of the last 12 months amounting to 0.87.
How has CLVS stock performed recently?
Clovis Oncology Inc. [CLVS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.04. With this latest performance, CLVS shares dropped by -31.54% in over the last four-week period, additionally sinking by -47.02% over the last 6 months – not to mention a drop of -81.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLVS stock in for the last two-week period is set at 32.46, with the RSI for the last a single of trading hit 26.12, and the three-weeks RSI is set at 36.71 for Clovis Oncology Inc. [CLVS]. The present Moving Average for the last 50 days of trading for this stock 1.1554, while it was recorded at 1.0100 for the last single week of trading, and 1.5442 for the last 200 days.
Clovis Oncology Inc. [CLVS]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Clovis Oncology Inc. [CLVS] shares currently have an operating margin of -148.09 and a Gross Margin at +73.90. Clovis Oncology Inc.’s Net Margin is presently recorded at -177.82.
Clovis Oncology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.20.
Insider trade positions for Clovis Oncology Inc. [CLVS]
There are presently around $38 million, or 30.70% of CLVS stock, in the hands of institutional investors. The top three institutional holders of CLVS stocks are: VANGUARD GROUP INC with ownership of 11,223,237, which is approximately -9.115% of the company’s market cap and around 0.40% of the total institutional ownership; MILLENNIUM MANAGEMENT LLC, holding 5,400,324 shares of the stock with an approximate value of $4.81 million in CLVS stocks shares; and BLACKROCK INC., currently with $4.2 million in CLVS stock with ownership of nearly -52.71% of the company’s market capitalization.
Positions in Clovis Oncology Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 33 institutional holders increased their position in Clovis Oncology Inc. [NASDAQ:CLVS] by around 6,001,270 shares. Additionally, 95 investors decreased positions by around 19,313,488 shares, while 32 investors held positions by with 17,160,538 shares. The mentioned changes placed institutional holdings at 42,475,296 shares, according to the latest SEC report filing. CLVS stock had 13 new institutional investments in for a total of 1,157,873 shares, while 42 institutional investors sold positions of 4,556,031 shares during the same period.